Thoracic mobile aortic mural thrombus (TAMT) of the aortic arch is a rare condition. We report 3 cases of symptomatic TAMT treated with systemic alteplase (tissue plasminogen activator [t-PA]) thrombolysis. The first patient was symptomatic with repetitive thromboembolism to the left brachial artery. She was treated with repetitive thrombolysis after surgical embolectomy of the brachial artery. The second patient was symptomatic with splenic infarction and mesenteric ischemia. She was treated with a single cycle of systemic thrombolysis followed by ileocoecal resection. The third patient presented with a TAMT obstructing the left common carotid artery, causing ischemic stroke. After systemic thrombolysis, a reduction in thrombus size was documented; however, the patient died later, of acute heart failure, during the clinical course. On follow-up 6 months after the incidences, the 2 surviving patients were in good condition and free of thromboembolic events. We show that systemic thrombolytic therapy can be performed successfully in patients with TAMT.
Introduction
Mobile aortic mural thrombus (AMT) is a rare condition, accounting for a minority of peripheral arterial embolism. 1, 2 Most AMT involve the abdominal aorta (AAMT). In the case of thoracic aortic mural thrombi (TAMTs), the descending aorta and the distal arch are mostly affected with a predilection for the aortic isthmus. 3, 4 The pathogenesis of AMT appears to be heterogeneous and multifactorial. In general, local and systemic pathogenetic factors can be subdivided. Local endothelial lesions, mostly of atherosclerotic nature, serve as points of origin for thrombus formation. 1, 4, 5 States of hypercoagulability due to hematologic or oncologic diseases 6-10 promote thrombus formation, and the association between inflammatory bowel disease and mural thrombi has been published. 11 Finally, steroid medications have been incriminated in promoting thrombosis of the aorta. 3 Therapeutic experience is limited; there are not any widely accepted regimes available for TAMT. Medical therapy consisting of anticoagulation with heparin or a vitamin K antagonist is suggested especially for asymptomatic patients. 6, 12 Techniques of surgical treatment depend on the location of thrombus adhesion in the aorta and encompass thrombectomy, segmental endarterectomy, segmental resection, and reconstruction by patch aortoplasty or graft replacement. [12] [13] [14] [15] [16] Resection of thrombi in the thoracic aorta in general depends on the use of cardiopulmonary bypass, and, if the aortic arch needs to be inspected, deep hypothermic circulatory arrest may be required. 17 Interventional procedures, like endovascular stent-graft placement for the exclusion of AMT, are described in several case reports [18] [19] [20] [21] [22] but are not possible in the aortic arch.
In contrast to the numerous descriptions of conservative or surgical management of TAMT, systemic thrombolysis has rarely been described. Hausmann et al reported the successful lysis of an aortic arch thrombus in a patient after mesenteric embolism in 1992 (alteplase, 0.625 mg/kg body weight given every 24 hours for 3 days). 23 Ito et al presented successful alteplase infusion (4.13 mg bolus þ 37.15 mg over 60 minutes) in a case of a thrombus in the proximal ascending aorta causing massive myocardial infarction by occluding the left coronary artery, 24 and Durdil et al recently reported systemic alteplase thrombolysis (10 mg bolus þ 90 mg infusion over 60 minutes) of a thrombus attached to the wall of the descending thoracic aorta. 25 We describe 3 cases with systemic alteplase lysis of typical TAMT in the distal aortic arch.
Case 1
A 48-year-old female was admitted to a peripheral hospital with acute pain and pulselessness in the left arm due to an embolus in the left brachial artery. There was no history of venous or arterial thrombosis, an embolic event, or known cardiovascular disease. Recently, she had not been on medication, especially not on steroids.
Emergency surgical embolectomy of the left brachial artery was performed. Postoperatively, unfractionated heparin was administered, and the partial thromboplastin time (PTT) was kept between 50 and 70 seconds. In the following days, repeated embolic events occurred, always affecting the left arm. Overall, 6 re-embolectomies were necessary. Acetylsalicylic acid (ASS) was added to the medication, with a final dose of 500 mg per day.
A cardiac origin of the emboli was ruled out by transesophageal echocardiography (TEE). Subsequently performed computed tomography (CT) showed a thrombus attached to the inner curve of an otherwise nondiseased aortic arch ( Figure 1 ).
Based on the clinical suspicion of a type II heparin-induced thrombocytopenia (HIT II), anticoagulation was induced with lepirudin. The diagnosis of HIT II was later confirmed by laboratory tests, and thrombophilia screening was negative.
When the patient was referred to our institution, the diagnosis was confirmed by TEE, showing a free-floating thrombus, approximately 2 cm in diameter, attached to the caudal wall of the aortic arch directly opposite the left subclavian artery ( Figure 1 ). A second, much smaller thrombus was located in the descending aorta, approximately 3 cm distal to the first lesion. On TEE, the aorta was found to be nondiseased otherwise.
We performed systemic thrombolysis using alteplase (tissue plasminogen activator [t-PA]). Lepirudin was stopped 1 hour in advance of alteplase administration. A fibrinogen level exceeding 150 mg/dL was confirmed. Twenty milligrams of alteplase was given as a bolus injection over 5 minutes, followed by the continuous infusion of 100 mg of alteplase over 100 minutes via a peripheral vein. After finishing the alteplase infusion, lepirudin was started as soon as fibrinogen levels exceeding 150 mg/dL were confirmed again.
During alteplase infusion, active bleeding from the drain in the operative wound on the left arm was observed as the only side effect. Bleeding was easily controlled by a pressure bandage and stopped 1 hour after the end of the thrombolytic therapy. The blood loss was approximately 400 mL. After the treatment, the hemoglobin level and coagulation status were checked every 4 hours.
Control TEE after 24 hours showed the smaller, distal thrombus to be gone completely, while the larger, proximal thrombus had become significantly smaller.
For complete thrombolysis, a second cycle of alteplase infusion with the protocol mentioned above was started. This time, blood loss via the drain was more extensive, amounting to an additional 600 mL and requiring transfusion of 2 units of packed red blood cells (PRBCs).
Shortly before completion of the alteplase infusion, the patient complained about pain, weakness, and hypesthesia in the left lower leg and foot. On clinical examination, the distal pulses of the left leg were weaker but still palpable. After 10 minutes, the symptoms were completely gone; the patient had full strength in the left foot and no loss of sensation.
A whole body CT scan was performed immediately, which ruled out bleeding, arterial embolism, and any perfusion deficit. It also did not show any remaining thrombus in the aortic arch.
Anticoagulation with lepirudin titrated to a PTT of 50 to 70 seconds was continued until an international normalized ratio (INR) of 2.5 to 3.5 was reached using phenprocoumon, which was then used for 6 months. On follow-up visitation after 6 months, the patient was free of symptoms. Control CT scan did not reveal any pathology.
Case 2
A 47-year-old female presented to our emergency department with diffuse abdominal pain. Three months earlier, cervical carcinoma (pT2b pN0 G2 M0) had been diagnosed and treated by hysterectomy followed by outpatient radiochemotherapy with cisplatin. The last local irradiation of the pelvis was 2 days prior, and the last cisplatin administration was 5 days prior to the actual admission. The patient had been receiving 8 mg of dexamethasone daily since the last day of cisplatin administration.
Computed tomography scan showed an AMT at the aortic isthmus opposite to the left subclavian artery. There was suspicion of another, much smaller thrombus at the takeoff of the brachiocephalic trunk and a third one in the proximal descending aorta (Figure 2 ). Splenic infarction was the only intraabdominal finding at this early stage.
Clinically, however, acute mesenteric ischemia was suspected, with the serum lactate level constantly rising to about 5 mmol/L. Gastroduodenoscopy was negative. Treatment was initiated with lepirudin until heparin-induced thrombocytopenia was ruled out.
Systemic thrombolytic therapy was started to potentially treat both pathologies: TAMT and secondary mesenteric ischemia. Systemic alteplase lysis was performed 4 hours after admission according to the protocol described above with bolus injection and a continuous infusion. During alteplase infusion, no side effects were observed at all.
After thrombolytic therapy, the abdominal pain was still present. Control CT scan 12 hours after admission could not detect any thrombus; however, signs of intestinal ischemia and gangrene were seen. Laparotomy was immediately performed and ileocoecal resection of 90 cm of ileum and construction of an ileostoma were necessary. The intraoperative course was unremarkable, without any abnormal bleeding. In the pathological workup, no thrombi were detected in the resected arteries.
Postoperatively, anticoagulation to a PTT of 50 to 70 seconds was achieved with heparin, as both HIT and thrombophilia screening had not revealed any abnormalities. Thereafter, phenprocoumon therapy was established as in case 1. The patient was discharged on the 14th postoperative day. Six months after discharge, the patient was in good clinical condition without any evidence of new thromboembolic events. On CT, no aortic thrombi were detectable.
Case 3
An 84-year-old female presented to our emergency department somnolent with a global aphasia and a high-grade right-hand side hemiparesis. The symptoms started 2 hours prior. An accompanying relative reported repeated episodes of reduced vigilance and right-hand side weakness during the last days. Two weeks earlier, diagnostic coronary angiography was conducted due to a history of silent myocardial infarction.
Computed tomography scan revealed a thrombus in the aortic arch extending from the brachiocephalic trunk to the left common carotid artery. The left common carotid artery was completely obstructed by the thrombus. Cerebral ischemia was not visible on the initial cranial computed tomography (CCT), but reduced perfusion, predominantly of the medial cerebral artery, was documented on CT angiography.
We performed systemic alteplase thrombolysis with a 10-mg bolus and a continuous infusion of 60 mg of alteplase over 60 minutes. No complications occurred during the administration of alteplase. After completion of the thrombolysis, heparin was administered to a PTT of 50 to 70 seconds.
Initially, the neurological state improved compared to that on admission. The patient was vigilant and answered questions with simple answers. She was hemodynamically stable. Approximately 10 hours after thrombolysis, the patient was found comatose.
On CCT, central bleeding was ruled out. Cervical and thoracic angio-CT showed a moderate reduction in the thrombus size; however, the left common carotid artery was still completely obstructed.
The patient developed bradycardia and subsequent hemodynamic instability and respiratory insufficiency. Despite optimal intensive therapy, the patient died 13 hours after finishing the thrombolytic therapy. There was no hint of peripheral emboli or central or peripheral bleeding. Acute heart failure seemed to be the leading cause of death.
Discussion
Thoracic aortic mural thrombi remains a rare disease, even though in recent decades the diagnosis has been made more often and interest in the condition has emerged due to improved diagnostic methods. There is no consensus on the optimal therapeutic strategy of TAMT. Asymptomatic cases are mostly treated by anticoagulation alone 6 and careful follow-up. In the case of peripheral embolism, surgical or interventional procedures are essential. 12, 17 However, endovascular stent grafting is not advisable in the aortic arch. At least if repeated embolism occurs, the TAMT has to be removed. Surgical resection of the thrombus and the potentially underlying endothelial alteration was deemed to be the gold standard; however, depending on the site of thrombus adhesion, these procedures are quite complex and associated with relevant morbidity and mortality. 15 Aortic arch surgery generally depends on the use of hypothermic circulatory arrest, with or without the adjunct of selective cerebral perfusion. The mortality of these procedures in most series amounts to roughly 10%, showing a broad range depending on the nature and the acuteness of the underlying pathology. Additionally, there is a relevant risk of neurological (5%-10%) and nonneurological morbidity. 26, 27 In the emergency situation, mortality and morbidity exceeds these numbers by far.
However, as shown in case 2, the coincidence of a TAMT and an ongoing major thromboembolic event, like mesenteric ischemia, can cause a therapeutic dilemma, because both primary surgical thrombectomy of the aorta and primary laparotomy to treat mesenteric ischemia are associated with a particularly high perioperative risk triggered by the untreated pathology.
With the less invasive successful approach of systemic thrombolysis of TAMT, we reintroduce an alternative to extensive surgery in selected cases. We treated AMT of the abdominal aorta with thrombolysis as well. 28 Additionally, there is the possibility of a sequentially combined approach with thrombolysis in the acute setting of a symptomatic TAMT followed by elective surgery to treat the potentially underlying aortic pathology.
In the case of acute myocardial infarction, alteplase is usually administered at a dose of 100 mg over 90 minutes (15 mg bolus þ 0.75 mg/kg [maximum 50 mg] over 30 minutes þ 0.5 mg/kg [maximum 35 mg] over 60 minutes, ''accelerated infusion scheme'') 29 ; in the case of an ischemic stroke, 0.9 to 1.1 mg/kg is usually administered over 60 minutes, whereas 10% is given as a bolus. 30 The dose of alteplase in the first 2 cases (20 mg bolus þ 100 mg over 100 minutes) was chosen to be slightly higher because of the huge masses of thrombotic material. In case 3, we followed the recommended weight-adapted dose regimen for stroke with a bolus of 10 mg and a continuous infusion of 60 mg over 60 minutes because of the fear of secondary cerebral bleeding.
With the high-dose regimen, a complete thrombolysis could be achieved, in the first patient after 2 cycles and in the second patient after 1 cycle. However, using the reduced dose regimen in patient 3, no significant reduction in thrombus size and no recanalization of the obstructed left carotid artery was achieved.
Few drawbacks are associated with thrombolytic therapy of a TAMT in principle. First, the underlying endothelial pathology cannot be treated. This might be the major handicap, especially taking into account that the vast majority of the aortic arch thrombi seem to derive from small atherosclerotic plaques 4 and that just a minority seems to evolve from anatomic predilection sites like the insertion of the ligamentum arteriosum, with a rather normal intima. 15, 16 In our patients, no aortal or endothelial pathology was diagnosed by means of CT or TEE. In contrast, a hypercoagulable condition, HIT II, was diagnosed in the first patient, and an oncologic disease combined with steroid medication was present in the second patient, presumably being the main pathogenic factors for these individual TAMTs.
Second, when performing thrombolysis, the thrombus is not harvested and, for that reason, is not available for pathological workup. This is a substantial drawback of all interventional and conservative therapy strategies. However, if there is no pathology detectable radiologically or by means of TEE and, in particular, if a coagulation disorder is detected, we feel that it might be very improbable to detect malignancy in a thrombus. Consequently, the argument of harvesting the thrombus is not sufficient to justify the extensive surgery required.
Finally, thrombolysis of a TAMT comprises the potential threat that the pedicle of the thrombus is lysed faster than the corpus, causing massive arterial embolization. This problem is connected with anticoagulation alone and with every interventional manipulation of an AMT as well. With thrombolytic therapy, the experience is too limited to estimate the risk of such a thromboembolic event. However, emboli dissolving from an AMT are at least potentially treated by the systemic lysis therapy itself. If relevant peripheral embolism takes place, surgical embolectomy is still possible, especially taking into account that alteplase has a very short half-life of 3.5 to 5 minutes in the plasma. 31, 32 In our first case, obviously the complication of intratherapeutic peripheral embolism was directly treated by the causing therapeutic regimen itself. This limited experience with 3 patients makes us consider systemic thrombolysis to be a viable option for the treatment of TAMT. Factors which, in our opinion, make thrombolysis a favorable therapy option are the lack of radiological evidence of an aortal pathology and the existence of a systemic coagulation disorder. Furthermore, any site of AMT can be treated by this modality, which is the treatment of choice for the eventual occurrence of complicating emboli as well.
